Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation (PROACTIVE)
Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation: An Open-label Randomized Controlled Trial (PROACTIVE)
Sponsor: Hamilton Health Sciences Corporation
Listed as NCT04467086, this PHASE3 trial focuses on COVID and Critical Illness and remains completed. Sponsored by Hamilton Health Sciences Corporation, it has been updated 8 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Jun 2021 — Jan 2023 [monthly]
Recruiting PHASE3
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 3 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hamilton Health Sciences Corporation
- McMaster University
- Ottawa Hospital Research Institute
- Sinai Health System
- The Ottawa Hospital
For direct contact, visit the study record on ClinicalTrials.gov .